SEQUENCE LISTING

<110> COHERENT BIOPHARMA (SUZHOU) CO., LTD.; COHERENT BIOPHARMA (CAYMAN) CO., LTD.

<120> BI-LIGAND DRUG CONJUGATE AND USE THEREOF

<130> 066138-8002WO02

<160> 20

<170> PatentIn version 3 .5

<210> 1
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for Matripase
<400> 1
Lys Ser Arg Ala Glu Asp Glu
 1   5

<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for MMP-2
<400> 2
Pro Leu Gly Leu Ala Gly
 1   5

<210> 3
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for prostate-specific antigen
<400> 3
Ser Ser Leu Tyr
1

<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for TMPRSS2
<400> 4
Leu Leu Arg Ser Leu Ile Gly
 1   5

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for activated protein C
<400> 5

Leu Val Lys Arg
 1

<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for factor Ixa
<400> 6
Leu Val Val Arg
 1

<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for factor VIIa
<400> 7
Gln Leu Thr Arg
 1

<210> 8
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for factor Xa
<400> 8
Leu Glu Gly Arg
 1

<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for calpain-a
<400> 9
Pro Leu Phe Ala Glu Pro
 1   5

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for calpain-2
<400> 10
Gly Leu Gly Ser Glu Pro
 1   5

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for enteropeptidase
<400> 11
Asp Asp Asp Asp Lys
 1   5

<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for MMP-8
<400> 12
Gly Pro Ser Gly
 1

<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for proprotein convertase 5
<400> 13
Arg Ser Lys Arg
 1

<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Recognition site for calpain-3
<400> 14
Val Gly Val Phe
 1

<210> 15
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> P10
<400> 15
Cys Lys Glu Phe Leu His Pro Ser Lys Val Asp Leu Pro Arg
 1   5   10

<210> 16
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<400> 16
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Cys
 1   5   10

<210> 17

<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<400> 17
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
 1   5   10

<210> 18
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> MISC_FEATURE
<222> (6) ..(6)
<223> Xaa=D-Lys
<400> 18
Glu His Trp Ser Tyr Xaa Leu Arg Pro Gly Cys
 1   5   10

<210> 19
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> R9
<400> 19
Arg Arg Arg Arg Arg Arg Arg Arg Arg
 1   5

<210> 20
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Tat peptide
<400> 20
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln
 1   5   10